Pave Preps First-of-its-Kind Lung Biopsy Device

Posted: Updated:
Pave says its full core biopsy device gives clinicians a smaller needle than ever before to collect lung biopsies. Pave says its full core biopsy device gives clinicians a smaller needle than ever before to collect lung biopsies.

Lung cancer is the leading cause of cancer death, and doctors are clamoring for a better way to diagnose it. A Zionsville-based startup is creating a lung biopsy device that it says gives clinicians something they’ve never had before: a smaller needle and a safer tissue-collection process that produces a clearer diagnosis for the patient. Pave LLC leaders say it meets a critical need as personalized medicine transforms cancer treatment, because the advances demand a better biopsy.

“If you’re a patient, one of the things you really don’t want to hear is, ‘You went through this biopsy, you went through all this pain, and the tissue we received from this biopsy was non-diagnostic,’” says Pave President Doug Knoll. “In other words, you’re going to have to do this biopsy again.”

Pave believes it can reduce this scenario by giving doctors a better biopsy tool that collects more tissue in a single procedure. A lung biopsy involves removing samples of lung tissue with a special needle to determine if cancer or lung disease are present. Pave Chief Executive Officer Debb Beck says lung biopsies are especially difficult, because they carry unique challenges.

“Anytime you’re poking a hole in the lung, you have increased risk to the patient,” says Beck.

“Pneumothorax (collapsed lung) can occur, when air gets in between the lung and chest wall,” says Knoll. “It’s a very serious condition that can be dangerous, painful and may require medical intervention. The smaller the needle, the less risk of something like that happening.”

And that’s why Pave is aiming to give clinicians a smaller needle than ever before to collect lung biopsies: 20 gauge. But the full core biopsy device has another critical feature that Pave says differentiates it from conventional ones: a cone.

“Envision a tube…the furthest part of the tube has a very thin, sharp edge, and the cone extends into the interior of the tube until it hits the inner diameter,” says Knoll. “When that’s fired forward into tissue, the tissue is then compressed into the cannula (thin tube) and retained when removing the device.”

Pave says the innovative cone design enables the device to collect a larger amount of tissue, which opens the door to pinpointing personalized cancer treatments based on the genetics of the individual’s disease. A 2015 personalized cancer medicine trial led by the National Cancer Institute revealed that one in five samples—obtained using standard biopsy methods—didn’t have enough cancerous cells to analyze, and therefore, the patients couldn’t be matched with personalized treatments.

Pave leaders believe the device solves a major market need for lung biopsies: the collection of a large sample in a smaller-than-ever package size.

“The more tissue that you can get from a patient, the more biomarkers that are available within it; you’re able to do more testing on it and target your treatment plan accordingly,” says Knoll. “So, the ideal would be to have a needle that has the maximum amount of tissue collection capability for its size.”

Beck says Pave has also simplified the design of the full core biopsy device, describing it as lightweight and balanced. These factors are important during a CT scan when the doctor needs to walk away and leave the device in place to check the placement before firing. 

Pave got its start in 2015 as a spinoff from Promex Technologies, where three of the startup’s five founders held leadership positions; Texas-based Argon Medical Devices acquired Promex. Pave is currently testing prototypes, refining the device and working with Indianapolis-based venture development organization Elevate Ventures to prepare for fundraising.

“Making a device for full core biopsy is technically challenging to begin with,” says Beck, “and to make it in an even smaller size is even more challenging.”

 “We have a solution that allows the device to be simple to manufacture, cheap to manufacture and allows it to be extremely effective for the job; that’s our biggest strength,” says Knoll. “We’re pushing hard, because this is a wide-open opportunity.”          

Knoll says Pave’s device collects the larger samples pathologists need, while maintaining a small profile.
Beck says the device has characteristics that make it ideal for lung biopsies and other respiratory diseases that require biopsy.
  • Perspectives

    • What Makes Up Quality of Place?

      Economic development is a hot topic these days. With the economy continuing to chug along in robust fashion and unemployment approaching historic lows, communities are refining their objectives and priorities to eek every drop of benefit they can from these financially strong times. Nowhere is this focus greater than with “quality of place,” As cities and states think about how they can distinguish themselves from their peers, a common starting point is developing a...



Company Name:
Confirm Email:
INside Edge
Morning Briefing
BigWigs & New Gigs
Life Sciences Indiana
Indiana Connections


  • Most Popular Stories

    • Computer Science, Gaming Collide With 'Hour of Code'

      Elementary school students in the Metropolitan School District of Decatur Township in Indianapolis are getting an early lesson in coding through the international Hour of Code program. The initiative is designed to give people an introduction to computer science and coding, and Lynn Hodgkin, elementary media coordinator for the district, says it takes a game-centered approach to teaching coding to kids. The students are participating in the Hour of Code at the...

    • St. Vincent Names Manas Regional President

      Julie Manas has been selected to serve as regional president of the St. Vincent North Region, which includes St. Vincent Anderson, Carmel, Fishers, Kokomo, Mercy, Randolph and Williamsport hospitals. She has more than 30 years of healthcare experience and most recently comes from Hospital Sisters Health System, Western Wisconsin Division, where she held the role of president and chief executive officer.

    • The Heritage Group Founder to be Remembered

      Services are set for noted businessman and philanthropist Fred Fehsenfeld, founder of Indianapolis-based The Heritage Group, who passed away last week at the age of 94. Fehsenfeld, a graduate of Purdue University and decorated World War II veteran, will be remembered Saturday during a Celebration of Life, at The Center on the northwest side of Indianapolis.

    • On-Air

      Find out when and where you can watch and listen to our reports.

    • Holcomb Details 2019 Next Level Agenda

      Governor Eric Holcomb has unveiled his legislative and administrative priorities ahead of the 2019 Indiana General Assembly. The governor says his Next Level Agenda continues an ongoing focus on jobs, economic growth, health, infrastructure and government service. During a presentation Thursday, the governor also revealed his Next Level Trails program, which aims to provide $90 million in grants for new hiking, biking and riding trails throughout the state.